A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of a Medical Collagen Filler for Correcting Infraorbital Depression
Infraorbital hollowing, also known as tear trough deformity, refers to a sunken groove extending from the medial canthal region along the infraorbital rim downward and laterally. It is one of the key features of facial aging and remains one of the most challenging issues in periorbital rejuvenation [1,2]. This deformity is particularly common among Asian populations, with approximately 60%-70% of middle-aged individuals presenting with varying degrees of infraorbital hollowing [2]; its incidence increases significantly with age. The formation of infraorbital hollowing results from the combined effects of multiple factors, including anatomical changes, soft tissue atrophy, skin aging, and impaired lymphatic circulation [2]. Beyond compromising facial aesthetics, it creates negative impressions of fatigue, aging, and sternness, which can severely affect patients' psychological well-being and social lives [3]. In recent years, driven by growing demand for facial rejuvenation, infraorbital hollowing correction has become a popular non-surgical aesthetic procedure.
However, due to the complex anatomy of the infraorbital region-characterized by thin skin, abundant vasculature, and fragile lymphatic drainage-traditional fillers are prone to issues such as migration, the Tyndall effect, and prolonged swelling, placing higher demands on both filling materials and injection techniques [4]. Collagen, as a natural biomaterial, offers distinct advantages for infraorbital hollowing correction owing to its excellent biocompatibility, low migration tendency, and light-scattering properties [5]. The mechanism of collagen injection for infraorbital hollowing correction is a complex, multi-stage, and multi-level process that achieves immediate physical volumization and tissue support. Injected collagen replenishes lost volume, forming a soft, cohesive fibrous structure that lifts the depressed area and restores a smooth transition between the lower eyelid and cheek, thereby reducing the hollowed appearance [5,6]. Meanwhile, due to its high adhesiveness, collagen binds loosened skin tissues together, repositions the disrupted fibrous scaffold network, and restores a youthful, firm contour [6]. After injection, the collagen gradually dehydrates and condenses, reorganizing into a fibrillar structure resembling native collagen in vivo, which further tightens tissues and enhances the supporting effect.
The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. was approved for marketing by the NMPA in 2016 (Registration Certificate No.: Guo Xie Zhu Zhun 20163131609). It is indicated for dermal filling of the face to correct moderate to severe nasolabial folds, and has demonstrated favorable efficacy and safety in clinical practice. The proposed new indication is infraorbital filling for the improvement and correction of infraorbital hollowing. The objective of this study is to evaluate the efficacy and safety of this medical collagen filler manufactured by Feifan (Changchun) Medical Biotechnology Co., Ltd. in correcting the severity of infraorbital hollowing. In accordance with the Measures for the Administration of Medical Device Registration and Filing, the Good Clinical Practice for Medical Device Clinical Trials (GCP), and the Guidelines for Medical Device Clinical Trial Design, and adhering to the ethical principles of the World Medical Association Declaration of Helsinki, this study strives to maximize benefits for research participants while minimizing potential harm.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Hongqiang Li
- 电话号码:0431-85085090
- 邮箱:azhudezhuziyu@163.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Aged 18 years or older (based on the time of signing the informed consent form), of any gender; Assessed by the blinded investigator, both eyes must exhibit moderate to severe infraorbital hollowing (i.e., an Allergan Infraorbital Hollowing Scale [AIHS] grade of 2-3), and the participant must desire improvement in the infraorbital hollowing; Able to complete the efficacy self-assessment without wearing framed glasses (wearing contact lenses for self-assessment is acceptable); Able and willing to follow the investigator's instructions, comply with the treatment restrictions specified in this protocol, and attend all scheduled study visits; Voluntarily participating in this clinical trial and signing the research participant informed consent form.
Exclusion Criteria:
- 1. Known allergy to collagen, any component of the investigational product, or any local anesthetic (e.g., lidocaine or other amide-type anesthetics); 2. History of severe allergic reactions (e.g., anaphylactic shock, laryngeal edema, asthma, dyspnea, hypotension, syncope shortly after exposure to an allergen); 3. Presence of scars, deformities, unhealed wounds, or other conditions in the planned injection area and bilateral midface that may interfere with efficacy evaluation or increase treatment risk, potentially compromising visual assessment of the infraorbital rim, or active/recurrent inflammation or infection in either eye; 4. Previous treatment with any permanent filler (e.g., polymethylmethacrylate [PMMA], silicone, expanded polytetrafluoroethylene [ePTFE]), autologous fat, or unknown injectables in the planned injection area and bilateral midface; 5. Treatment with poly-L-lactic acid (PLLA), polycaprolactone (PCL), calcium hydroxylapatite (CaHA), or similar agents in the planned injection area and bilateral midface within 24 months prior to screening or planned during the trial period; 6. Treatment with cross-linked sodium hyaluronate, animal-derived collagen, or similar agents in the planned injection area and bilateral midface within 12 months prior to screening or planned during the trial period; 7. Treatment with recombinant human-like collagen, botulinum toxin, or similar agents in the planned injection area and bilateral midface within 6 months prior to screening or planned during the trial period; 8. History of active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis); 9. Treatment with non-cross-linked sodium hyaluronate filler or cosmetic procedures (e.g., intense pulsed light [IPL], radiofrequency, dermabrasion, laser, chemical peels) in the planned injection area and bilateral midface within 6 months prior to screening; 10. Previous lower blepharoplasty or facial lift/brow lift within 12 months prior to screening; 11. In the investigator's judgment, presence of large lower eyelid fat pads affecting treatment or excessive pigmentation in the infraorbital area (excluding dark circles not caused by hyperpigmentation); 12. History of keloids or keloid-prone constitution (hypertrophic scarring tendency); 13. Chemotherapy, immunosuppressants, immunomodulatory therapy (e.g., monoclonal antibodies), or systemic corticosteroids (except inhaled corticosteroids) within 3 months prior to screening; 14. Screening liver function tests showing ALT and/or AST > 2 × upper limit of normal (ULN), or renal function tests showing Cr > 1.5 × ULN, and deemed by the investigator as unsuitable for the trial; 15. History of bleeding disorders (e.g., porphyria, coagulation factor deficiency, coagulopathy, or platelet disorders); clinically significant abnormal coagulation function at screening (e.g., APTT > 1.5 × ULN); or receipt of anticoagulant, antiplatelet, or thrombolytic therapy (e.g., warfarin, heparin, aspirin) within 2 weeks prior to screening; 16. In the investigator's judgment, severe dysfunction of vital organs (e.g., brain, heart, lung, liver, kidney), such as severe cardiovascular or cerebrovascular diseases (hospitalization for myocardial infarction or cardiac surgery, congestive heart failure, or myocardial infarction within 3 months; severe unstable arrhythmia; hypertrophic cardiomyopathy; severe aortic stenosis; aneurysm; stroke), severe pulmonary diseases (moderate to severe pneumonia, respiratory failure), or uncontrolled diabetes; 17. Epilepsy, mental disorders, or other severe neuropsychiatric conditions that may preclude completion of trial follow-up; 18. Lactating women or those planning pregnancy during the study period; 19. Participation in another interventional clinical trial within 1 month prior to screening; 20. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Varying degrees of Infraorbital Depression
|
The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores
大体时间:3 months after the last injection in the experimental group and at 3 months after randomization in the control group
|
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores at 3 months after the last injection in the experimental group and at 3 months after randomization in the control group, as evaluated by blinded investigator |
3 months after the last injection in the experimental group and at 3 months after randomization in the control group
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- FimanPharma-Xuanwu Hospital
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.